DIRS.INFO The most relevant business & tech news

☆ Jim Cramer's top 10 things to watch in the stock market Wednesday: New dawn for JNJ, Disney push, Meta upgrade
▼ + stars: | 2023-04-05 | by ( Jim Cramer | ) www.cnbc.com time to read: +4 min

Meta Platforms (META) price target raised to $250 from $225 at Jeffries. Federal Realty (FRT) price target lowered to $111 from $118 at Piper Sandler. Bank of America raises price target for Apple to $168 from $158, keeps a neutral rating on shares. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

☆ Club meeting recap: Jim Cramer says 'the existential threat is gone for J&J'
▼ + stars: | 2023-04-05 | by ( Paulina Likos | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Jim Cramer said Wednesday that J & J's proposal could mean, "the existential threat is gone for J & J." Watch Eli Lilly Club holding Eli Lilly (LLY) will report a key phase-3 data readout of its Alzheimer's drug Donanemab in the next one-to-two months. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

☆ Premarket stocks: These are the only stocks that matter right now
▼ + stars: | 2023-04-05 | by ( Nicole Goodkind | ) edition.cnn.com time to read: +7 min

Leading the way in growth are tech stocks like Apple (AAPL), Microsoft (MSFT), Alphabet (GOOGL), Amazon (AMZN), Tesla (TSLA) and Meta (FB). That’s been a boon to large cap tech stocks that are more sensitive to interest rates because they tend to borrow more than established companies and rely more on the prospect of future earnings. But it also means that the current market rally is thin, as the major indexes outperform the average stock. Strong outperformance from the largest stocks often power indexes to rise, said Liz Ann Sonders, chief investment strategist at Schwab, in a note Tuesday. But healthy markets should be characterized by greater participation of the “soldiers” — the rest of the stocks, she said.

☆ Going against the grain: We're nibbling on weakness and selling into strength
▼ + stars: | 2023-04-04 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

We are buying 20 shares of Caterpillar (CAT) at roughly $217.39 and selling 20 shares of Eli Lilly (LLY) at roughly $355.11. With the market dumping the cyclicals and favoring the defensives today, we are going against the grain by nibbling on weakness (Caterpillar) and selling into strength (Eli Lilly). As for Eli Lilly, the recent rotation back into pharmaceutical stocks has pushed LLY back near $360, which is about where it started in 2023. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

☆ Lilly says experimental Alzheimer's drug reduces amyloid in small study
▼ + stars: | 2023-03-31 | by ( Deena Beasley | ) www.reuters.com time to read: +3 min

The higher the dose of the antibody drug, which was given by subcutaneous injection, the larger the effect, Lilly said. The Indianapolis-based drugmaker is launching a Phase III study of the experimental antibody, remternetug, but declined to comment on which doses will be selected for larger, later-stage trials. Lilly, at a medical conference in Gothenburg, Sweden, presented interim data from 41 study participants. Trial results published last year showed that, in patients with early Alzheimer's, Leqembi reduced the rate of cognitive decline by 27% compared with a placebo. Brooks said that sharing its early remternetug data "reinforces Lilly's commitment and investment in the Alzheimer's disease space ...

Stock Chart Icon Stock chart icon Nvidia's stock performance year to date. Stock Chart Icon Stock chart icon Meta's stock performance year to date. Stock Chart Icon Stock chart icon Devon Energy's stock performance year to date. Stock Chart Icon Stock chart icon Johnson & Johnson's stock performance year to date. Stock Chart Icon Stock chart icon Honeywell's year to date stock performance.

☆ As weight-loss drugs hit the U.S. market, doctors debate how to use them
▼ + stars: | 2023-03-30 | by ( Patrick Wingrove | ) www.reuters.com time to read: +6 min

[1/2] The American Medical Association logo is seen at their office in Washington, D.C., U.S., August 30, 2020. REUTERS/Andrew Kelly/March 30 (Reuters) - As powerful new obesity drugs enter the U.S. market, medical associations are keen to advise their members on how to best use them for patients. "These new compounds are game changers, there's no doubt about it," said Anthony Comuzzie, chief executive of The Obesity Society. The group last provided obesity treatment guidelines in 2013 alongside the American Heart Association and American College of Cardiology. OBESITY AS A DISEASEThe American Medical Association, the nation’s largest medical group, recognized obesity as a disease in 2013.

REUTERS/Daniel BecerrilLONDON, March 29 (Reuters) - Drugs that combat obesity could for the first time be included on the World Health Organization's "essential medicines list," used to guide government purchasing decisions in low- and middle-income countries, the U.N. agency told Reuters. A panel of advisers to the WHO will review new requests for drugs to be included next month, with an updated essential medicines list due in September. The request to consider obesity drugs was submitted by three doctors and a researcher in the United States. The majority – 70% - live in low- and middle-income countries. EXPANDING ACCESSIncluding obesity drugs among the WHO's essential medicines could have great significance for that population.

☆ Here's our March rapid-fire update on all 36 stocks in Jim Cramer's Investing Club portfolio
▼ + stars: | 2023-03-28 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +13 min

Here's a rapid-fire update on every stock in the CNBC Investing Club portfolio. But importantly, the chipmaker has joined Apple in rarified air, becoming an "own it, don't trade it" stock for the Club. The company's business can withstand an economic slowdown and benefits from a weaker U.S. dollar because of its large international presence. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

☆ Viking joins obesity drug race after promising early trial data
▼ + stars: | 2023-03-28 | by ( Mariam Esunny | ) www.reuters.com time to read: +2 min

March 28 (Reuters) - Viking Therapeutics Inc's (VKTX.O) experimental obesity drug helped reduce weight and was safe in an early-stage study, the company said on Tuesday, sparking a 60% rise in its shares. While Novo Nordisk (NOVOb.CO) already has its obesity drug, Wegovy, in the market, Eli Lilly is expecting approval for its treatment later this year. That could also make Viking a potential acquisition target, Laidlaw & Company analyst Yale Jen said. Viking said it was planning to test higher doses of the drug over a longer treatment window in a mid-stage trial, versus a shorter limit in the current, early-stage trial. Shares of Viking were trading at $14.15, bringing the drugmaker closer to a market capitalization of $1 billion.

☆ Novartis buoyed by trial success in early-stage breast cancer
▼ + stars: | 2023-03-27 | by ( Ludwig Burger | ) www.reuters.com time to read: +2 min

The Swiss firm's shares jumped 5.8% on Monday to a four-week high by 0734 GMT, after it said a panel of independent supervisors recommended stopping the trial early because an interim analysis had shown a clear benefit. Kisqali has been approved to treat hormone-driven breast cancer that has spread to other body parts, where it has taken market share from Pfizer's (PFE.N) Ibrance. Rival drug Verzenio by Eli Lilly (LLY.N) has approval in the early setting for women at high risk of recurrence after surgery. Kisqali, which saw sales gain 31% to $1.2 billion last year, is one of two new drugs with a particularly important role for the group's future sales growth. Detailed trial results will be presented at a medical conference, Novartis said, without identifying the meeting or its timing.

If successful, Amgen would claim ownership of all antibodies that inhibit the PCSK9 protein, the mechanism of action for both Repatha and Praluent. Other companies could then do the same with their own antibody treatments in other disease areas. The case might also affect newer technologies used in medicine, such as CRISPR gene editing and messenger RNA, she said. A Washington, D.C.-based federal appeals court that covers U.S. patent cases invalidated Amgen's patent claiming ownership of all PCSK9 inhibitors as a whole in 2021. Amgen sued Sanofi and Regeneron in 2014.

March 21 (Reuters) - Altimmune Inc's (ALT.O) experimental obesity drug helped reduce weight by over 10% on average in a mid-stage trial, the company said on Tuesday, but safety concerns sent its shares tumbling more than 50%. Wolleben added that the drug showed " a little bit worse" tolerability than previous data. Patients who received a 2.4 milligram dose of Altimmune's experimental drug, pemvidutide, achieved average weight loss of 10.7% at the end of week 24, the company said. The data looked competitive to mid-stage data from Novo Nordisk's (NOVOb.CO) obesity drug Wegovy and Eli Lilly's (LLY.N) candidate for the condition, most analysts said. While Novo Nordisk's drug Wegovy is already available, Lilly expects approval for its obesity drug candidate, tirzepatide, this year.

☆ Morgan Stanley's case for six Club names, including Alphabet and Microsoft
▼ + stars: | 2023-03-21 | by ( Paulina Likos | ) www.cnbc.com time to read: +6 min

In a research note Tuesday, Morgan Stanley identified its "best long-term picks" for 2025, in line with our approach for assessing companies. Six names on Morgan Stanley's list were Club holdings, all of which the firm rated a buy. Alphabet (GOOGL): Morgan Stanley analysts think artificial intelligence (AI) will create a new growth opportunities at Google parent Alphabet in its core products, including its search engine, YouTube and cloud offerings. Morgan Stanley has price target of of $135 per share on the stock. Eli Lilly (LLY): The pharmaceuticals giant is well-positioned within the U.S. due to its strong pipeline of drugs and "robust new product cycles," Morgan Stanley analysts argued.

☆ For investors looking for solid ground in an uncertain market, balance sheet is king
▼ + stars: | 2023-03-20 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +6 min

Amid ongoing market volatility and renewed fears about the health of the banking sector, investors and analysts are increasingly targeting the stocks of companies with stellar balance sheets. Note: The Altman Z-score is derived from a model initially developed in the 1960s by New York University professor Edward Altman as a way to predict bankruptcies. We used an Altman Z-score of 5 to focus our list on the cream of the crop. Tier 1 Capital ratios are generally a better metric for monitoring the balance sheets of big banks. But the market may give heightened attention to companies with strong balance sheets in times of elevated economic uncertainty.

☆ Amgen to cut 450 jobs in second round of layoffs this year
▼ + stars: | 2023-03-17 | by ( ) www.reuters.com time to read: +1 min

March 16 (Reuters) - Amgen Inc (AMGN.O) said on Thursday it would cut 450 jobs, or less than 2% of its workforce, making it the company's second round of layoffs this year amid intensifying pressure on drug prices and high inflation. "We made these changes to realign our expense base in the face of intensifying pressure on drug prices and high levels of inflation," a company spokeswoman said in a statement to Reuters. Layoffs by U.S. companies over January and February this year touched the highest since 2009, a report showed. The biotech company forecasted 2023 revenue in a range of $26 billion to $27.2 billion, while analysts had estimated $27.17 billion. Reporting by Akanksha Khushi and Deena Beasley; Editing by Rashmi Aich and Subhranshu SahuOur Standards: The Thomson Reuters Trust Principles.

☆ Sanofi to cut US price of its most-prescribed insulin by 78%
▼ + stars: | 2023-03-16 | by ( Patrick Wingrove | ) www.reuters.com time to read: +3 min

In addition to Lantus, Sanofi said it will cut by 70% the list price for its fast-acting insulin, Apidra. The branded list price of Lantus is $438.07 for the pre-filled pens and $292.07 for a 10 ml vial. Rival Novo Nordisk on Tuesday said it would cut U.S. list prices for several insulin products by up to 75% next year. That followed Lilly's March 2 decision to cut list prices by 70% for Humalog and Humulin, its most commonly prescribed insulin products. Most Americans with insurance do not regularly pay list price for insulin, but they may have an insurance co-pay based on the drug's list price or pay full price up to a certain amount of money spent.

The Alzheimer's Association and the pharmaceutical industry say the drug companies are not directly involved in the campaign. But the Alzheimer's Association says patients simply don't have the time to spare. The agency did not address the Alzheimer's Association campaign. Association members have met 30 times with staffers for the state's 20 members of Congress, Ryan Schiff, the chapter's public policy manager, said. Spokespeople for all three companies said they do not work with the Association on its campaign to expand Medicare coverage of the drugs.

☆ Playing defense as market tumbles — 10 stocks that outperform in recessions
▼ + stars: | 2023-03-16 | by ( Michelle Fox | ) www.cnbc.com time to read: +4 min

As the market tumbles and recession risks rise, it's time to start playing defense and buying stocks that are poised to outperform in the later innings of the U.S. market cycle, according to Wolfe Research. Bond yields have fallen, oil prices have steeply dropped and stock market volatility has surged. With that in mind, here are 10 of the stocks that Wolfe Research believes outperform the rest of the market during a recession. It has an estimated 2023 P/E of 24.7x and an EV/2023 estimated EBITDA of 16.4x. The drugmaker has an estimated 2023 P/E of 37.2x and an EV/2023 estimated EBITDA of 28.7x.

☆ Sanofi to cut price of its most-prescribed insulin by 78% in US
▼ + stars: | 2023-03-16 | by ( ) www.reuters.com time to read: 1 min

March 16 (Reuters) - Sanofi SA (SASY.PA) said on Thursday it would cut U.S. list prices by 78% for its most-prescribed insulin product starting next year, following rivals Novo Nordisk (NOVOb.CO) and Eli Lilly and Co (LLY.N). The move comes as U.S. President Joe Biden has pushed to extend to most Americans the $35 cap on out-of-pocket insulin costs made available to Medicare recipients by the Inflation Reduction Act. Novo Nordisk and Eli Lilly bowed to political pressure earlier this month to make these life-sustaining diabetes treatments more affordable. Reporting by Patrick Wingrove in New York, Pratik Jain in Bengaluru; Editing by Maju SamuelOur Standards: The Thomson Reuters Trust Principles.

☆ Here are Thursday's biggest analyst calls: Credit Suisse, Amazon, Block, First Republic, FedEx & more
▼ + stars: | 2023-03-16 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Here are Thursday's biggest calls on Wall Street: JPMorgan reiterates Amazon as overweight JPMorgan said growth deceleration concerns are overdone. Stifel upgrades FedEx to buy from hold Stifel said FedEx shares are compelling at current levels. JPMorgan reiterates Credit Suisse as overweight JPMorgan said it's standing by shares of the banking giant. JPMorgan upgrades Motorola Solutions to overweight from neutral JPMorgan called the telecom equipment company "high quality." Bank of America upgrades Takeda Pharmaceuticals to buy from neutral Bank of America said called Takeda a "stable value stock."

☆ Club meeting recap: Cramer outlines the Club stocks that are well-positioned in a volatile economy
▼ + stars: | 2023-03-15 | by ( Paulina Likos | ) www.cnbc.com time to read: +3 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Bank woes pressure stocks Stocks that work Stick with China-exposed names 1. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

☆ How GSK plans to replenish its depleted medicine cabinet
▼ + stars: | 2023-03-15 | by ( Maggie Fick | ) www.reuters.com time to read: +6 min

GSK has since suffered a series of clinical trial setbacks in its cancer drugs portfolio, most recently last year involving ovarian cancer drug Zejula and blood cancer drug Blenrep. BLOCKBUSTER POTENTIALAnalysts say that despite a string of strong quarterly earnings, lingering concerns over the company's drug pipeline reflect in GSK's share price. The investor said he does not see enough GSK drugs, either on the market or in development, with potential to be a so-called "blockbusters" with annual sales exceeding $1 billion. But Wood said the overhauled R&D department has put GSK in a strong position to meet growth targets. U.S. regulatory approval on GSK's vaccine, and a rival vaccine developed by Pfizer, is expected in May.

☆ Unfairly swept up in Wednesday's sell-off, these stocks now look more attractive
▼ + stars: | 2023-03-15 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +5 min

Another Club stock with defensive characteristics is Procter & Gamble (PG). The three companies have very little economic sensitivity, and our overarching reasons for owning them haven't changed: Eli Lilly for its innovative drug pipeline, J & J for its sterling balance sheet and upcoming breakup and Humana for the growth fueled by its retooled Medicare Advantage offering. Plus, their stocks have largely been out of favor in 2023, especially the drugmakers in Eli Lilly and J & J; shares of both companies are down more than 10% year to date. META 1Y mountain Meta Platforms (META) stock performance over the past 12 months. Meta shares rallied into the close, climbing 1.9%, to nearly $198 apiece.

Although insulin list prices are high in the U.S., drugmakers typically pay substantial rebates to private insurers and government programs, resulting in lower prices for most Americans with insurance. U.S.-listed Novo Nordisk shares rose as much as 1.7% to $142.95, while Denmark-listed shares closed marginally higher on Tuesday. Eli Lilly shares were down slightly. "I think it is a relatively natural consequence of what we have seen their competitor Eli Lilly do. Eli Lilly, Sanofi and Novo Nordisk make up 90% of the U.S. market for insulin.

Search resuls for: "LLY"

25 mentions found